Centene Corporation
CNC
$58.23
-0.07%
Centene Corporation is a leading managed care organization specializing in government-sponsored healthcare plans, primarily Medicaid, Medicare, and individual exchange offerings, serving approximately 20 million medical members. The company is a dominant player in the Medicaid managed care market, leveraging its scale and expertise in administering complex, state-sponsored programs to secure a significant competitive position. The current investor narrative is heavily influenced by sector-wide regulatory developments, particularly the recent announcement of a larger-than-expected 2027 Medicare Advantage payment increase by CMS, which has improved revenue visibility and sparked a positive re-rating across managed care stocks, including Centene.…
CNC
Centene Corporation
$58.23
Investment Opinion: Should I buy CNC Today?
The synthesized recommendation is Hold. The core thesis is that while CNC is deeply undervalued and benefits from a positive sector catalyst, the extreme volatility in its core profitability makes the investment case too speculative until earnings demonstrate consistency.
Supporting evidence includes a compelling valuation with a PS ratio of 0.10 and EV/Sales of 0.12, representing a significant discount to industry peers. Revenue growth remains robust at 21.86% YoY, and the company generates substantial free cash flow ($4.32B TTM). However, these positives are counterbalanced by a net margin of -3.43%, a forward PE of 13.06x that is only valid if profits materialize, and analyst sentiment that remains largely neutral, indicating institutional caution.
Key risks that could invalidate a Buy thesis are: 1) Another quarter of significant net losses, and 2) A failure to capitalize on the improved Medicare Advantage payment environment. This Hold rating would upgrade to a Buy if the company reports two consecutive quarters of positive net income, confirming a profitability turnaround, and the PS ratio remains below 0.15x. It would downgrade to a Sell if revenue growth decelerates below 10% YoY or if net losses widen sequentially. Relative to its history and peers, the stock is undervalued on a sales basis, but this discount is justified by its poor and volatile earnings quality.
Sign up to view all
CNC 12-Month Price Forecast
The investment case for CNC is a classic battle between compelling valuation/sector tailwinds and dire company-specific fundamentals. The 30% probability bull case offers significant upside if management stabilizes profits, but the 50% probability base case of volatile consolidation is more likely. The stance is neutral due to this high uncertainty; the stock is not a clear buy until earnings become predictable. Confidence is medium because the data is contradictory—the powerful rally suggests a changing narrative, but the financials have not yet confirmed it. The stance would upgrade to bullish on two consecutive quarters of positive net income. It would downgrade to bearish if the next earnings report shows another substantial loss.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Centene Corporation's 12-month outlook, with a consensus price target around $75.70 and implied upside of +30.0% versus the current price.
Average Target
$75.70
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$47 - $76
Analyst target range
Analyst coverage appears limited with only 4 analysts providing estimates, indicating this large-cap stock may have subdued institutional research interest. The consensus sentiment, inferred from recent institutional ratings, is neutral, with firms like JP Morgan, Mizuho, and Morgan Stanley maintaining 'Neutral' or 'Equal Weight' stances, though Barclays upgraded to 'Overweight' in January 2026. The average revenue estimate for the forward period is $213.1 billion, with a range from $207.7 billion to $218.3 billion, but a specific consensus price target is not provided in the data. The wide range between the low and high revenue estimates signals meaningful uncertainty among analysts regarding the company's near-term financial trajectory. The pattern of recent ratings shows stability, with no downgrades in the provided sample, suggesting analysts are in a 'wait-and-see' mode following the stock's powerful rally and pending clearer evidence of sustained fundamental improvement.
Bulls vs Bears: CNC Investment Factors
The bull case, centered on extreme undervaluation, strong revenue growth, and a powerful sector catalyst, currently holds stronger evidence, as reflected in the stock's explosive 60% six-month rally. However, the bear case presents a formidable counter-argument rooted in the company's severe and volatile profitability, which directly challenges the sustainability of the rally. The single most important tension in the investment debate is whether the recent positive sector news and valuation discount are sufficient to overcome the company's profound and recent earnings instability. The resolution hinges on CNC demonstrating a clear and sustained path to normalized, positive net income in upcoming quarters.
Bullish
- Extreme Valuation Discount to Peers: CNC trades at a trailing PS ratio of 0.10 and an EV/Sales of 0.12, a deep discount to typical managed care peers trading above 0.5x sales. This represents a significant margin of safety and potential for multiple expansion if profitability stabilizes, as the stock is valued at a point of extreme pessimism relative to its own historical range.
- Robust Revenue Growth and Scale: The company reported 21.86% YoY revenue growth in Q4 2025 to $49.73 billion, with the Medicaid segment generating $37.65 billion. This demonstrates strong underlying demand for its government-sponsored healthcare plans and its dominant market position serving 20 million members.
- Powerful Sector-Wide Catalyst: The recent CMS announcement of a larger-than-expected 2027 Medicare Advantage payment increase is a major positive sector catalyst, improving revenue visibility. This news has driven a powerful 54.97% stock rally in the past month, signaling a fundamental re-rating of the managed care sector.
- Strong Cash Flow Generation: Despite recent net losses, the company generated $4.32 billion in trailing twelve-month free cash flow. This robust cash generation provides a crucial buffer, enabling debt management and operational flexibility, mitigating near-term liquidity concerns from reported earnings volatility.
Bearish
- Severe and Volatile Profitability: CNC reported a net loss of -$1.1 billion in Q4 2025 with a net margin of -3.43%, following a catastrophic -$6.63 billion loss in Q3 2025. This extreme volatility, swinging from a $1.31 billion profit in Q1 2025, indicates deep operational challenges and unreliable earnings power.
- Elevated Short Interest and Skepticism: A short ratio of 2.34 suggests significant investor skepticism about the sustainability of the recent rally. This high short interest represents a potential overhang, as any negative news could trigger a sharp reversal as short sellers cover or amplify selling pressure.
- Valuation Dependent on Recovery: The stock's compelling valuation (PS of 0.10) is entirely predicated on a recovery from severe profitability issues. The forward PE of 13.06x, while reasonable, is only meaningful if the company returns to consistent profitability, which recent quarterly losses cast doubt upon.
- Analyst Uncertainty and Neutral Stance: Analyst coverage is limited (4 firms) with a consensus neutral stance, as evidenced by recent 'Neutral' and 'Equal Weight' ratings from major banks. The wide revenue estimate range ($207.7B to $218.3B) reflects significant uncertainty about the company's near-term financial trajectory.
CNC Technical Analysis
The stock is in a powerful recovery trend, having surged 60.17% over the past six months and 54.97% in the last month, decisively reversing a prior downtrend evidenced by a -2.98% one-year change. As of the latest close at $58.27, the price is trading at approximately 94% of its 52-week high of $62.21, indicating strong momentum and positioning near recent highs, which suggests investor optimism but also raises the risk of near-term overextension. Recent momentum is exceptionally strong and diverges positively from the longer-term trend; the 1-month gain of 54.97% vastly outpaces the 3-month gain of 43.59%, signaling a sharp acceleration in buying pressure that has propelled the stock from its 52-week low of $25.08. The stock's beta of 1.062 indicates volatility roughly in line with the broader market, but the extreme short-term moves highlight significant stock-specific catalysts. Key technical support is anchored at the 52-week low of $25.08, while immediate resistance lies at the 52-week high of $62.21; a sustained breakout above $62.21 would confirm the strength of the new uptrend, whereas a failure here could lead to consolidation. The stock's 1-month relative strength of +49.37 versus the SPY's +5.6% underscores its dramatic outperformance during this rally phase.
Beta
1.06
1.06x market volatility
Max Drawdown
-60.0%
Largest decline past year
52-Week Range
$25-$62
Price range past year
Annual Return
-5.7%
Cumulative gain past year
| Period | CNC Return | S&P 500 |
|---|---|---|
| 1m | +52.6% | +4.0% |
| 3m | +41.2% | +8.2% |
| 6m | +62.0% | +11.5% |
| 1y | -5.7% | +24.3% |
| ytd | +39.4% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CNC Fundamental Analysis
Revenue growth remains robust, with Q4 2025 revenue of $49.73 billion representing a 21.86% year-over-year increase, though this follows a volatile profitability pattern across quarters. The Medicaid segment, at $37.65 billion, is the primary revenue driver, while the Commercial segment contributed $10.79 billion. Profitability is currently under pressure, as evidenced by a net loss of -$1.1 billion and a net margin of -3.43% in the latest quarter, with gross margin at 12.24% and operating margin at -3.91%. The quarterly trend shows severe volatility, swinging from a net income of $1.31 billion in Q1 2025 to a loss of -$6.63 billion in Q3 2025, indicating significant one-time charges or operational challenges that have disrupted earnings consistency. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.94, and liquidity is solid with a current ratio of 1.68. Crucially, the company generates substantial cash flow, with trailing twelve-month free cash flow of $4.32 billion, providing strong internal funding capacity for operations and potential debt reduction, which mitigates the near-term concerns from reported losses.
Quarterly Revenue
$49.7B
2025-12
Revenue YoY Growth
+0.21%
YoY Comparison
Gross Margin
+0.15%
Latest Quarter
Free Cash Flow
$4.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CNC Overvalued?
Given the negative trailing net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.10, while the forward-looking valuation is better assessed via the EV/Sales multiple of 0.12, both indicating a very low sales multiple. The minimal gap between these figures suggests the market is not pricing in significant near-term sales multiple expansion. Compared to industry averages, Centene's EV/Sales of 0.12 represents a deep discount to the typical managed care peer, which often trades above 0.5x sales, reflecting the market's punitive assessment of its recent profitability woes and operational volatility. Historically, the stock's own PS ratio has fluctuated widely; the current PS of 0.10 is near the lower end of its historical range observed in the provided data (e.g., 0.35x to over 1.0x in recent years), suggesting the stock is being valued at a point of significant pessimism relative to its own history, which could present a value opportunity if fundamentals stabilize.
PE
-3.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -72x~220x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are centered on severe earnings volatility and margin pressure. The company swung from a $1.31 billion net income in Q1 2025 to a -$6.63 billion loss in Q3 2025, culminating in a -$1.1 billion loss in Q4 2025 with a net margin of -3.43%. This erratic profitability, coupled with a gross margin of just 12.24% in the latest quarter, indicates potential underlying cost control or pricing issues in its Medicaid/Medicare plans. While strong free cash flow of $4.32 billion provides a cushion, the debt-to-equity ratio of 0.94 represents a moderate leverage burden that could become problematic if losses persist.
Market & Competitive Risks include valuation compression if the recent rally proves premature. The stock has surged 54.97% in one month and trades at 94% of its 52-week high, raising the risk of a pullback if upcoming earnings fail to validate the optimism. Its beta of 1.062 suggests market-correlated volatility, but the extreme short-term moves are stock-specific. The primary external risk is regulatory reversal; while the recent CMS payment news was positive, future government reimbursement rates for Medicaid and Medicare are perpetually subject to political and budgetary pressures, which could compress margins. Competitive intensity in the managed care sector remains high, pressuring pricing.
Worst-Case Scenario involves a failure to stabilize profitability, leading to a loss of investor confidence and a re-test of recent lows. A chain of a disappointing earnings report, combined with a broader market downturn, could trigger the high short interest (ratio 2.34) to aggressively amplify selling. This could see the stock retreat towards its 52-week low of $25.08, representing a potential downside of approximately -57% from the current price of $58.27. The historical max drawdown of -60.52% shows such severe declines are within the realm of possibility for this name.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: The extreme quarterly earnings volatility, with a swing from a $1.31B profit to a -$6.63B loss within the same year, indicates fundamental instability in cost management or pricing. 2) Execution Risk: The company must prove it can translate 21.86% revenue growth and sector tailwinds into consistent profits. 3) Valuation & Sentiment Risk: The stock has surged 55% in one month; a failure to deliver on raised expectations could lead to a sharp pullback, exacerbated by high short interest (ratio 2.34). 4) Regulatory Risk: Despite recent positive news, long-term government reimbursement rates for Medicaid and Medicare are subject to political and budgetary pressures.
The 12-month forecast presents three scenarios. The Base Case (50% probability), target $55-65, assumes gradual improvement with ongoing volatility, leading to consolidation near current levels. The Bull Case (30% probability), target $70-85, requires a successful profitability turnaround and multiple expansion. The Bear Case (20% probability), target $30-45, involves further earnings deterioration and a retreat towards the 52-week low of $25.08. The Base Case is most likely, as it aligns with the current neutral analyst sentiment and the high uncertainty reflected in the wide range of revenue estimates ($207.7B to $218.3B). The key assumption is that profitability recovery will be slow and uneven.
CNC is deeply undervalued on a sales basis but fairly valued or overvalued on an earnings basis, depending on recovery prospects. Its trailing PS ratio of 0.10 and EV/Sales of 0.12 represent a steep discount to managed care industry peers, which often trade above 0.5x sales. This suggests the market is pricing in significant distress. However, with a negative trailing PE and a forward PE of 13.06x (which assumes a return to profitability), the stock is not cheap if earnings do not materialize. The valuation implies the market expects continued operational challenges, offering a large margin of safety if the company recovers, but no margin of safety if it does not.
CNC presents a high-risk, high-potential-reward opportunity, making it a good buy only for specific investors. For value investors comfortable with volatility and turnaround situations, the extreme valuation discount (PS 0.10) and strong cash flow ($4.32B) are compelling. However, the severe and recent earnings volatility, including a -$1.1B net loss last quarter, makes it a speculative bet. The average analyst stance is neutral, reflecting this uncertainty. It could be a good buy for those who believe the positive CMS news and management execution will swiftly resolve profitability issues, but it is not suitable for conservative or income-focused investors.
CNC is primarily suitable for a medium- to long-term investment horizon of 2-3 years, not short-term trading. The thesis is a value-based turnaround, which requires time for management to execute and for quarterly earnings to demonstrate a sustained recovery. The stock's high beta (1.062) and recent extreme volatility make it risky for short-term traders. Furthermore, it pays no dividend, eliminating an income component. Investors should be prepared to hold through potential volatility while awaiting concrete evidence of normalized profitability. A minimum holding period of 12-18 months is suggested to properly assess whether the operational turnaround is taking hold.
